Frailty in Patients With Lung Cancer: A Systematic Review and Meta-Analysis.
elderly
frailty
lung cancer
mortality
outcome
Journal
Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
29
08
2021
revised:
14
02
2022
accepted:
16
02
2022
pubmed:
27
2
2022
medline:
11
8
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
Previous studies regarding the prevalence of frailty in patients with lung cancer and mortality in frail patients with lung cancer are inconsistent and require clarification. What is the prevalence and impact of frailty in patients with lung cancer? This systematic review and meta-analysis used a combination of free-text terms and medical subject headings terms, according to the database requirements in MEDLINE/PubMed, Scopus, and Cochrane Library from inception until November 15, 2020. A total of 2,571 articles were identified, and 16 articles involving 4,183 patients were included for study. The prevalence of frailty in lung cancer was 45% (95% CI, 28-61; I The prevalence of frailty in lung cancer is 45%, which has a significant negative impact on survival of patients with lung cancer. These results highlight the importance of measuring frailty, which provides important prognostic information, and may provide opportunities for interventions to improve outcomes in patients with lung cancer.
Sections du résumé
BACKGROUND
Previous studies regarding the prevalence of frailty in patients with lung cancer and mortality in frail patients with lung cancer are inconsistent and require clarification.
RESEARCH QUESTION
What is the prevalence and impact of frailty in patients with lung cancer?
STUDY DESIGN AND METHODS
This systematic review and meta-analysis used a combination of free-text terms and medical subject headings terms, according to the database requirements in MEDLINE/PubMed, Scopus, and Cochrane Library from inception until November 15, 2020.
RESULTS
A total of 2,571 articles were identified, and 16 articles involving 4,183 patients were included for study. The prevalence of frailty in lung cancer was 45% (95% CI, 28-61; I
INTERPRETATION
The prevalence of frailty in lung cancer is 45%, which has a significant negative impact on survival of patients with lung cancer. These results highlight the importance of measuring frailty, which provides important prognostic information, and may provide opportunities for interventions to improve outcomes in patients with lung cancer.
Identifiants
pubmed: 35217002
pii: S0012-3692(22)00391-9
doi: 10.1016/j.chest.2022.02.027
pii:
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
485-497Subventions
Organisme : Medical Research Council
ID : MR/T02481X/1
Pays : United Kingdom
Informations de copyright
Copyright © 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.